Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 9/20 | 0.54 |
| ▸ | DDB1 | Q16531 | 5/20 | 0.48 |
| ▸ | IKZF2 | Q9UKS7 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 4/20 | 0.41 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.41 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23812336 | 0.90 | CRBN (0.57) | CRBNDDB1IKZF2GSPT1PRKAA2 | |
| SCHEMBL23812267 | 0.84 | CRBN (0.54) | CRBNDDB1CYP3A4CYP2C9PRKAA2 | |
| SCHEMBL23812268 | 0.80 | CRBN (0.53) | CRBNDDB1IKZF2GSPT1PRKAA2 | |
| SCHEMBL30577952 | 0.79 | CRBN (0.56) | CRBNDDB1PRKAA2 | |
| SCHEMBL30577953 | 0.78 | CRBN (0.55) | CRBNDDB1PRKAA2HSD11B1 | |
| SCHEMBL13490509 | 0.77 | BCHE (0.51) | CYP3A4CYP2C9 | |
| SCHEMBL171346 | 0.76 | CYP3A4 (0.49) | CYP3A4CYP2C9 | |
| SCHEMBL23812335 | 0.75 | CRBN (0.57) | CRBNDDB1IKZF2PRKAA2 | |
| SCHEMBL23799184 | 0.74 | CRBN (0.61) | CRBNDDB1GSPT1 | |
| SCHEMBL30577939 | 0.73 | CRBN (0.53) | CRBNDDB1GSPT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210284624-A1 | IMMUNOMODULATORY COMPOUNDS | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210284624-A1 | IMMUNOMODULATORY COMPOUNDS | CRBN, CD47, CD58 | CRBN 1/4885DDB1 1466/4885IKZF2 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.